Drug Trial Radar · NCT04947137
Development of a Normative Database for Rheumatoid Arthritis (RA) Imaging With Tc99m Tilmanocept
Last checked: Nov 20, 2026Latest source record: Jan 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
134
Actual
Start
May 27, 2021
Primary completion
Jan 21, 2022
Study completion Jan 21, 2022
Sponsor
- Lead sponsor
- Navidea BiopharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Jul 1, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will establish a normative database of Tilmanocept Uptake Values (TUVjoint) in healthy controls age-matched to the RA population.
Conditions
- Rheumatoid Arthritis
Interventions
Tc99m tilmanoceptDrug
Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Normal Limits of TUVjoint in Healthy SubjectsTime frame: Up to 39 days
- Qualitative Evaluation of SPECT/CT for Tilmanocept LocalizationTime frame: Up to 39 days
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
San Marcus Research Clinic
Miami Lakes, Florida
Innovation Medical Research Center
Palmetto Bay, Florida
Kettering Medical Center
Kettering, Ohio
Essential Medical Research
Tulsa, Oklahoma
Altoona Center for Clinical Research
Duncansville, Pennsylvania
Sun Research Institute
San Antonio, Texas
Tranquility Research
Webster, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.